Heinrich Heine University Düsseldorf

James Hardie Industries Announces Management Appointments

Retrieved on: 
Thursday, November 3, 2022
Other Construction & Property, Construction & Property, Other Manufacturing, Manufacturing, James Hardie Industries, Business administration, Company, VP, London Business School, Growth, Air Liquide, ESG, Industry, Transformation, Heinrich Heine University Düsseldorf, NYSE, MIT Sloan School of Management, ASX, 2nd Floor (Nina song), CEO, Harcourt Street, Harvard Business School, Executive education, JHX, Media release, Management, Tarkett

James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announces the appointment of Christian Claus as President Europe.

Key Points: 
  • James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announces the appointment of Christian Claus as President Europe.
  • Mr. Claus joins James Hardie as President Europe from a successful leadership career in large global industrial B2B and B2B2C businesses.
  • James Hardie assumes no obligation to update or correct the information contained in this Media Release except as required by law.
  • James Hardie Industries plc is a limited liability company incorporated in Ireland with its registered office at Europa House, 2nd Floor, Harcourt Centre, Harcourt Street, Dublin 2, D02 WR20, Ireland
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221103006359/en/

EQS-News: Three disruptive approaches in biotechnology and medicine win the BioRiver Boost! 2022 biotech start-up competition

Retrieved on: 
Wednesday, October 5, 2022
Statistics, California Governor's Office of Economic Development, Medicine, Bayer, Miltenyi Biotec, Digitalization, Virus, Science, QIAGEN, Organization, Biotechnology, Teaching hospital, Cosmetics, Energy, RWTH Aachen University, Technology, Technical, Industry, Economic development, CEO, Association, Protein, Food, Ministry, City, Economy, Digital economy, Heinrich Heine University Düsseldorf, Ministry of Economic Affairs and Climate Policy, Fine chemical, Auction, Wood-plastic composite, Fuel oil, Innovation

Three disruptive approaches in biotechnology and medicine win the BioRiver Boost!

Key Points: 
  • Three disruptive approaches in biotechnology and medicine win the BioRiver Boost!
  • Three disruptive approaches in biotechnology and medicine win the BioRiver Boost!
  • 2022 biotech start-up competition
    Dsseldorf/Hilden, October 5th, 2022: The winner of this years BioRiver Boost!
  • In its ninth iteration, on September 29, 2022, BioRiver Boost!, selected the three best young European-based companies.

Tapping Into Consumers' Needs, EveLab Insight Introduces a 3D Panoramic AI Skin Analyzer for Advanced Skincare

Retrieved on: 
Monday, August 22, 2022
Beauty, 3D, Trust, Research, HOW, Environmental medicine, Cheek, Innovation Center station, WHY, HHU, Health, Skin, Heinrich Heine University Düsseldorf, Software as a service, GLOBE, E-commerce, Eve, ERIC, Ascential, Science, WHAT, Culture, Cosmetics, Perfume, Dermatology

According to a beauty insight report fromEdge, 56% of consumers favor skincare products more now than they did before the pandemic.

Key Points: 
  • According to a beauty insight report fromEdge, 56% of consumers favor skincare products more now than they did before the pandemic.
  • They want skincare products that will deliver the results they want, and above all, they care about trust and authenticity.
  • EveLab Insight, a beauty business SaaS solution provider, has recently introduced its latest innovative technology: Eve V, a 3D panoramic artificial intelligence skin analyzer.
  • Based on award-winning algorithms and patented technologies, EveLab Insight offers both a hand-held skin analyzer and a photo-based skin analysis app.

The New Germany Fund, Inc. Announces Portfolio Manager Change

Retrieved on: 
Thursday, May 26, 2022
Banking, Professional Services, Finance, Master of Science, Terrorism, GF, Investment, Coronavirus, DWS Group, Nature, Heinrich Heine University Düsseldorf, War, DWS, Bachelor of Science, Sale, Fund, NYSE, Security (finance)

The New Germany Fund, Inc. (NYSE: GF) (the Fund) announced today that Leon Cappel will replace Philipp Schweneke as the Funds deputy portfolio manager effective June 1, 2022.

Key Points: 
  • The New Germany Fund, Inc. (NYSE: GF) (the Fund) announced today that Leon Cappel will replace Philipp Schweneke as the Funds deputy portfolio manager effective June 1, 2022.
  • Valerie Schuler will continue to serve as the Funds portfolio manager.
  • For more information on the Fund, including the most recent month-end performance, visit www.dwsfunds.com or call (800) 349-4281.
  • There is a one-time public offering and once issued, shares of closed-end funds are sold in the open market through a stock exchange.

ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 18, 2022
Coronavirus Scientific Advisory Board (Turkey), Neurodegeneration, Patient, Lists of diseases, Intention, Person, PMN, Disease, PROMIS, GLOBE, Neuropsychiatric Disease and Treatment, AD, Epitope, Program, Company, ALS, Heinrich Heine University Düsseldorf, Employment, Therapy, PD, DISC1, TSX, Toronto Stock Exchange, Brain, Neuroscience, University, Amyotrophic lateral sclerosis, Vaccine, Medical device, Schizophrenia

Schizophrenia is a clinical term for a severely disabling neuropsychiatric disease that disrupts employment, families and communities, and likely has heterogenous biological origins.

Key Points: 
  • Schizophrenia is a clinical term for a severely disabling neuropsychiatric disease that disrupts employment, families and communities, and likely has heterogenous biological origins.
  • A candidate for a key misfolding protein in schizophrenia was first identified in a Scottish family with a neurodevelopmental syndrome including schizophrenia, such that the gene was named disrupted in schizophrenia (DISC1).
  • Dr. Carsten Korth, biological psychiatrist and pioneer on the role of DISC1 in chronic mental illness, has been recruited to the ProMIS Scientific Advisory Board to share his expertise and scientific acumen on this subject.
  • We now have tools including ProMIS proprietary computational algorithms to approach schizophrenia and related diseases for druggable misfolded protein targets, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer.

Dr Frank Wiegand, Experienced Neuroscience Leader Joins Beckley Psytech as Chief Medical Officer

Retrieved on: 
Wednesday, November 3, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Heinrich Heine University Düsseldorf, Depression, Esketamine, Humboldt University of Berlin, Research, Heriot-Watt University, University, Neuropsychiatric Disease and Treatment, Knowledge, Pharmacy, Patient, Beckley Foundation, J&J, Neuropharmacology, Business administration, Leadership, Marketing, Johnson & Johnson, Suicide, CEO, Growth, Postgraduate certificate, CMO, Lists of diseases, Doctor of Philosophy, Brain, Pharmaceutical industry

Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where he most recently held the position of Vice President, Global Medical Affairs in Neuroscience.

Key Points: 
  • Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where he most recently held the position of Vice President, Global Medical Affairs in Neuroscience.
  • Cosmo Feilding Mellen, CEO of Beckley Psytech, said: Following our highly successful series B fundraise and as our lead psychedelic compounds begin to enter the clinic, we are thrilled to be welcoming Dr. Wiegand as our Chief Medical Officer.
  • Dr. Frank Wiegand, CMO of Beckley Psytech, said: I am truly excited to be joining the leadership team at Beckley Psytech as we usher in a new age in the research, development and delivery of psychedelic medicines.
  • I am thrilled to be joining the inventive and passionate team at Beckley Psytech, where we will work relentlessly to make this dream a reality.